In the setting of intensive immunosuppression for the management of rejection in solid organ
transplant (SOT) recipients, or graft-versus-host disease (GVHD) in hematopoietic stem cell …

The mTOR pathway has a central role in the regulation of cell metabolism, growth and
proliferation. Studies involving selective gene targeting of mTOR complexes (mTORC1 and …

Belatacept, a costimulation blocker, may preserve renal function and improve long‐term
outcomes versus calcineurin inhibitors in kidney transplantation. This Phase III study …

Advances in maintenance immunosuppression over the past three decades have improved
solid organ transplantation outcomes dramatically. Uninterrupted access to …

Advances in immunosuppression have propelled kidney transplantation from a scientific
curiosity to the optimal treatment for patients with end stage kidney disease. Declining rates …

Background Non-nephrotoxic immunosuppressive strategies that allow reduction of
calcineurin-inhibitor exposure without compromising safety or efficacy remain a goal in …

The clinical profile of belatacept in kidney transplant recipients was evaluated to determine if
earlier results in the BENEFIT study were sustained at 3 years. BENEFIT is a randomized 3 …

Introduction: The mTOR (mechanistic target of rapamycin, formerly known as mammalian
target of rapamycin) kinase is centrally involved in the regulation of cell growth and …

Safety and efficacy of two sirolimus (SRL)-based regimens were compared with tacrolimus
(TAC) and mycophenolate mofetil (MMF). Renal transplantation recipients were randomized …

Sirolimus (SRL) allows to minimize the use of cyclosporine (CsA), but de novo
administration after transplantation is associated with various complications. We report a …